Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9050311 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(1 year, 3 months from now) | |
US7417070 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Jul, 2026
(3 years from now) | |
US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(5 years from now) | |
US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(5 years from now) | |
US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(5 years from now) | |
CN103274926A | UNITED THERAP | Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(5 years from now) | |
CN103274926B | UNITED THERAP | An Improved Method For Preparing Active Components In The Curved Remodulin |
Dec, 2028
(5 years from now) | |
CN101903324A | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(5 years from now) | |
CN101903324B | UNITED THERAP | A Kind Of Preparation Of Active Composition In Remodulin Curved Latanoprost Is Improved Method |
Dec, 2028
(5 years from now) | |
IN201003640P4 | UNITED THERAP | An Improved Process To Prepare Treprostinil,The Active Ingredient In Remodulin |
Dec, 2028
(5 years from now) | |
IN287697B | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(5 years from now) | |
EP2252570A1 | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ® |
Dec, 2028
(5 years from now) | |
EP2252570B1 | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ® |
Dec, 2028
(5 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9422223 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(1 year, 3 months from now) | |
US8252839 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(1 year, 3 months from now) | |
US9278901 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(1 year, 3 months from now) | |
US7544713 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Jul, 2024
(1 year, 5 months from now) | |
US9393203 | UNITED THERAP | Osmotic drug delivery system |
Apr, 2026
(3 years from now) | |
US8410169 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Feb, 2030
(7 years from now) | |
US8349892 | UNITED THERAP | Solid formulations of prostacyclin analogs |
Jan, 2031
(7 years from now) | |
US8747897 | UNITED THERAP | Osmotic drug delivery system |
Aug, 2031
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Oct 18, 2022 |
Orphan Drug Exclusivity (ODE) | Oct 18, 2026 |
Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient
Market Authorisation Date: 20 December, 2013
Treatment: Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1).; Method of treating pulmonary hypertension by orally administering a formulation of a pharmaceutically acceptable salt of treprostinil; A method of treating pulmonary hypertension and pulmonary arterial hypertension by administering an oral osmotic pharmaceutical dosage form; A method of oral delivery of treprostinil comprising administering an oral osmotic pharmaceutical dosage form
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(5 years from now) | |
US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(5 years from now) | |
CN103274926A | UNITED THERAP | Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(5 years from now) | |
CN103274926B | UNITED THERAP | An Improved Method For Preparing Active Components In The Curved Remodulin |
Dec, 2028
(5 years from now) | |
CN101903324A | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(5 years from now) | |
CN101903324B | UNITED THERAP | A Kind Of Preparation Of Active Composition In Remodulin Curved Latanoprost Is Improved Method |
Dec, 2028
(5 years from now) | |
IN201003640P4 | UNITED THERAP | An Improved Process To Prepare Treprostinil,The Active Ingredient In Remodulin |
Dec, 2028
(5 years from now) | |
IN287697B | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(5 years from now) | |
EP2252570A1 | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ® |
Dec, 2028
(5 years from now) | |
EP2252570B1 | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ® |
Dec, 2028
(5 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9199908 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(1 year, 3 months from now) | |
US10076505 | UNITED THERAP | Inhalation formulations of Treprostinil |
Dec, 2024
(1 year, 10 months from now) | |
US9713599 | UNITED THERAP | Parenteral formulations of treprostinil |
Dec, 2024
(1 year, 10 months from now) | |
US10695308 | UNITED THERAP | Inhalation formulations of treprostinil |
Dec, 2024
(1 year, 10 months from now) | |
US8653137 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Sep, 2028
(5 years from now) | |
US8658694 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Sep, 2028
(5 years from now) | |
US7999007 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Mar, 2029
(6 years from now) |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 21 May, 2002
Treatment: Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration; A method of treating pulmonary hypertension comprising parenterally administering a formulation comprising a) 0.1 to 5% w/v of treprostinil or a pharmaceutically acceptable salt thereof and b) a citrate buffer; A method of treating a human patient suffering from pulmonary hypertension; Administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration
Dosage: INJECTABLE;IV (INFUSION), SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(5 years from now) | |
US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(5 years from now) | |
CN103274926A | UNITED THERAP | Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(5 years from now) | |
CN103274926B | UNITED THERAP | An Improved Method For Preparing Active Components In The Curved Remodulin |
Dec, 2028
(5 years from now) | |
CN101903324A | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(5 years from now) | |
CN101903324B | UNITED THERAP | A Kind Of Preparation Of Active Composition In Remodulin Curved Latanoprost Is Improved Method |
Dec, 2028
(5 years from now) | |
IN201003640P4 | UNITED THERAP | An Improved Process To Prepare Treprostinil,The Active Ingredient In Remodulin |
Dec, 2028
(5 years from now) | |
IN287697B | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(5 years from now) | |
EP2252570A1 | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ® |
Dec, 2028
(5 years from now) | |
EP2252570B1 | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ® |
Dec, 2028
(5 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10376525 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(4 years from now) | |
US10716793 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(4 years from now) | |
US9339507 | UNITED THERAP | Treprostinil administration by inhalation |
Mar, 2028
(5 years from now) | |
US9358240 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2028
(5 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Mar 31, 2024 |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 30 July, 2009
Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device
Dosage: SOLUTION;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(5 years from now) | |
US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(5 years from now) | |
CN103274926A | UNITED THERAP | Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(5 years from now) | |
CN103274926B | UNITED THERAP | An Improved Method For Preparing Active Components In The Curved Remodulin |
Dec, 2028
(5 years from now) | |
CN101903324A | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(5 years from now) | |
CN101903324B | UNITED THERAP | A Kind Of Preparation Of Active Composition In Remodulin Curved Latanoprost Is Improved Method |
Dec, 2028
(5 years from now) | |
IN201003640P4 | UNITED THERAP | An Improved Process To Prepare Treprostinil,The Active Ingredient In Remodulin |
Dec, 2028
(5 years from now) | |
IN287697B | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(5 years from now) | |
EP2252570A1 | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ® |
Dec, 2028
(5 years from now) | |
EP2252570B1 | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ® |
Dec, 2028
(5 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10130685 | UNITED THERAP | Diketopiperazine salts for drug delivery and related methods |
Aug, 2025
(2 years from now) | |
US10716793 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(4 years from now) | |
US10772883 | UNITED THERAP | Diketopiperazine microparticles with defined specific surface areas |
Jun, 2030
(7 years from now) | |
US10421729 | UNITED THERAP | Microcrystalline diketopiperazine compositions and methods |
Apr, 2035
(12 years from now) |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 23 May, 2022
Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device
Dosage: POWDER;INHALATION
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic